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Abstract
Pancreatic islet transplantation into the liver provides a possibility to treat selected patients with brittle type 1 diabetes mellitus.
However, massive early b-cell death increases the number of islets needed to restore glucose homeostasis. Moreover, late
dysfunction and death contribute to the poor long-term results of islet transplantation on insulin independence. Studies in
recent years have identiﬁed early and late challenges for transplanted pancreatic islets, including an instant blood-
mediated inﬂammatory reaction when exposing human islets to the blood microenvironment in the portal vein and the
low oxygenated milieu of islets transplanted into the liver. Poor revascularization of remaining intact islets combined with
severe changes in the gene expression of islets transplanted into the liver contributes to late dysfunction. Strategies to overcome
these hurdles have been developed, and some of these interventions are now even tested in clinical trials providing a hope to
improve results in clinical islet transplantation. In parallel, experimental and clinical studies have, based on the identiﬁed
problems with the liver site, evaluated the possibility of change of implantation organ in order to improve the results. Site-
speciﬁc differences clearly exist in the engraftment of transplanted islets, and a more thorough characterization of alternative
locations is needed. New strategies with modiﬁcations of islet microenvironment with cells and growth factors adhered to the
islet surface or in a surrounding matrix could be designed to intervene with site-speciﬁc hurdles and provide possibilities to
improve future results of islet transplantation.
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DOI: 10.3109/03009734.2010.548609Clinical pancreatic islet transplantation has, since the
introduction of the concept, been almost exclusively
performed through the intraportal route to the liver
based on the pioneering work of the late Dr Paul Lacy
(1). Early results of allogeneic islet transplantation
were poor, with insulin independence 1 year post-
transplantation less than 10% (2). However, in more
recent years, transplantation of pancreatic islets from
deceased donors has become a curative treatment for
selected patients with type 1 diabetes (3,4). Never-
theless, many problems still remain, including
massive early islet cell death (5). The intravascular
injection of pancreatic islets has been shown to elicit
an instant blood-mediated inﬂammatory reaction
(IBMIR) triggered by tissue factor and cyto/
chemokines expressed by pancreatic islets in the whole
blood microenvironment of the portal vein (6,7).
Moreover,thelivertissuehasaverylowoxygentension
(8,9), high numbers of resident macrophages (Kupffer
cells) (10), and possibly also high concentrations of
immunosuppressive drugs exposing the islet cells fol-
lowing intestinal uptake of the drugs. This means that
in most cases at least two donor pancreases are needed
to restore glucose homeostasis, which is far more than
the alleged 10%–20% of the total islet volume sug-
gested to be enough to maintain normoglycaemia in
humans (3). Despite the large transplanted islet mass,
the functional capacity of the transplanted islets has
been shown to correspond to only about 20% of that
found in a non-diabetic person (11). Within the ﬁrst
years post-transplantation most patients revert to insu-
lindependence if not re-transplanted. However, only
low doses of exogenous insulin are then usually
needed, and the major problems with hypoglycaemic
attacks most often no longer exist. It is presently
unknown whether the progressive decline in islet graft
function is site-speciﬁc or applies also to other implan-
tation sites.
Challenges for pancreatic islets early after
transplantation
A thrombotic reaction and complement cascade is
elicited when human islets are exposed to blood,
which is manifested by islet entrapment in blood clots,
leucocyte inﬁltration, predominantly neutrophil gran-
ulocytes, and disruption of the islet morphology (12)
(Figure 1). This so-called IBMIR occurs in clinical
islet transplantation as shown by an increase in
concentrations of thrombin–antithrombin complex
immediately after islet infusion, and the parallel
increase in c-peptide release indicates massive b-
cell death (7). A study by combined positron emission
tomography and computed tomography (PET/CT)
technique indicates that early islet cell death can be
estimated to be approximately 25% in patients intra-
portally transplanted with islets (13). Besides innate
immune reactions, islets transplanted to the liver may
have restricted survival rates due to the low oxygen
tension in the liver parenchyma. Experimental studies
indicate that approximately 70% of the islets are
hypoxic 1 day after intraportal transplantation, as
evaluated by the biochemical marker pimonidazole
which accumulates in islet cells at oxygen tension
levels below 7.5–10 mmHg (14). Since this marker
is not accumulated in dead or dying cells, the number
of hypoxic cells may even be under-estimated. Clin-
ically, also high concentrations of immunosuppressive
drugs in the portal vein are likely to hamper islet
survival by direct toxic effects (15,16).
Experimentally, several sites besides the liver have
been tested for islet transplantation, including the
subcutis, muscle, the intraperitoneal site, the renal
subcapsular site, the spleen, bone-marrow, pancreas,
and the omental pouch. A more thorough character-
ization of engraftment has recently been performed
with regard to implantation of islets into the pancreas
or muscle. Orthotopic implantation of islets, i.e. into
the pancreas, has been described in experimental
settings (17,18). Although being the most physiolog-
ical environment for islets, the pancreas has rarely
been considered as a potential implantation organ in
clinical practice. Surgical interventions and injections
in the pancreas are difﬁcult, and there is a high risk of
acute complications due to leakage of enzymes from
the exocrine cells that causes tissue damage and
inﬂammation. Clearly, implantation techniques need
to be improved to minimize these early risks, e.g. by
subcapsular implantation of islets or other techniques.
Safety issues have also to be carefully investigated in
large-animal models. Nevertheless, studies in small
animals indicate that this site provides good conditions
for early survival of implanted islets, with minimal
inﬂammatory and ﬁbrotic components (19). More-
over, the oxygenation of the pancreas is much better
than the liver, with a mean oxygen tension in the
exocrine parenchyma of ~30 mmHg (20).
Striated muscle has clinically been tested as implan-
tation site for pancreatic islets based on the feasibility
of this site for autotransplantation of parathyroid
glands and its easy access. In one Swedish patient,
islets were, due to severe hereditary chronic pancre-
atitis, autotransplanted intramuscularly with a remain-
ing high and stable c-peptide production (21).
However, also this site seems to provide challenges
for early survival of the islets based on the extensive
ﬁbrosis occurring in the islet grafts (21,22). Especially
prominent central necrosis parts may occur in islet
grafts, if islets are implanted as clusters, and cause
central ﬁbrosis (23).
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transplantation
For pancreatic islets to survive and regain function
after transplantation they need to be properly revas-
cularized. Experimental studies show that mouse and
human islets transplanted intraportally are poorly
revascularized, similar to islets implanted subcapsu-
larly to the kidney or spleen (24–26). It is noteworthy
that endothelial cells seem to be stimulated to grow
towards the implanted islets, i.e. form a dense vascu-
lature in the immediate vicinity of the islets, but few
blood vessels enter the endocrine parenchyma. This is
reﬂected in an impaired oxygenation of intraportally
implanted islets that remains for at least 1month post-
transplantation, and that is accompanied by increased
apoptosis rates (Olsson R, Olerud J, Pettersson U,
and Carlsson P-O; unpublished observation). Late
maturation of the blood vessel system may occur,
since numbers of pimonidazole-positive islets, sug-
gesting prevailing hypoxia, decrease with time, and
apoptosis rates become similar to those in endoge-
nous islets at 3 months post-transplantation. Conse-
quences of low blood vessel numbers for islets are not
restricted merely to impaired oxygen and nutrient
transport but also include less inﬂuence of paracrine
supporting signals from islet endothelial cells on
b-cell function and growth. Islet endothelial cells
may normally support nutrient-stimulated insulin
release and b-cell differentiation by their secretion
of basement membrane components, especially lam-
inin, and the glycoprotein thrombospondin-1 seques-
tered to the islet matrix (27,28). Their secretion of
laminin and hepatocyte growth factor is of importance
to maintain b-cell proliferation and increase the
b-cell mass when functionally demanded (29,30).
Impaired drainage of islet hormones induced by a
no-ﬂow phenomenon in isolated islets and early after
transplantation also predisposes for sequestration of
islet amyloid polypeptide (IAPP) as amyloid in islets.
Irrespective of mechanism, amyloid formation has
been described to occur in isolated human islets
during culture (31) and following experimental trans-
plantation to the liver in mice (32). A recent autopsy
report of an islet-transplanted patient who died from a
myocardial infarct indicates that amyloid forms fol-
lowing clinical islet transplantation to the liver (33).
Late failure of islets transplanted to the liver may also
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Figure 1.Obstacles for successful pancreatic islet transplantation at different sites.
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nearby hepatocytes. Proof of principle of improved
long-term graft function has been shown in a rodent
model by blocking lipogenesis (34). Hepatic steatosis
has been reported in the clinical situation after islet
transplantation (35,36). There are reports on site-
speciﬁc alterations in islet function after intraportal
islet transplantation as well, such as defective gluca-
gon response to hypoglycaemia (37,38) caused by
increased glucose ﬂux and glucose levels within the
liver secondary to increased glycogenolysis caused
by systemic hyperglycaemia (39), and substantial
changes in the b-cell gene expression and function
(40,41). A perturbed glucose-stimulated insulin
release in intrahepatic islets has been shown to cor-
relate with defects in glucose oxidation, (pro)insulin
biosynthesis, and decreased insulin content and asso-
ciated with decreases in the islet gene expression of
the b-cell differentiation marker pancreatic and duo-
denal homeobox gene-1 (PDX-1) and key enzymes in
glucose transport and metabolism in the b-cells, such
as glucose transporter-2, glucokinase, pyruvate
carboxylase, and mitochondrial glycerol phosphate
dehydrogenase (41).
Pancreatic islets experimentally transplanted to the
pancreas are much better revascularized than intra-
hepatic islets (19). However, despite being implanted
into their normal physiological microenvironment,
intrapancreatically transplanted islets display some
functional and gene expression changes, although
not as profound as those observed in islets implanted
in the liver. A characteristic ﬁnding for intrapancrea-
tically transplanted islets seems to be their higher
insulin release compared with endogenous islets at
low glucose concentrations, and their high expression
of the lactate dehydrogenase-A gene, which is nor-
mally expressed in low levels in b-cells (41). This
may explain why animals receiving large numbers of
intrapancreatically transplanted islets are slightly
hypoglycaemic (18).
Pancreatic islets transplanted to striated muscle are
rapidly and much better revascularized than intrapor-
tally transplanted islets (23). This seems to be irre-
spective of whether the islets are implanted in clusters
or as single islets (22) and has been conﬁrmed in
patients autotransplanted with islets due to exocrine
pancreas disease (23). The functionality of the newly
formed capillaries is good, and oxygen tension
levels in intramuscular islet grafts were only slightly
decreased when compared to native islets (22).
Despite lack of direct portal drainage, pancreatic islets
implanted to muscle seem to have a superior function
when compared to intrahepatic islets (23), although
a prerequisite for this is the avoidance of cluster
formation at islet implantation (42).
Tentative strategies for islet microenvironment
modiﬁcation to improve islet graft survival and
function
Modiﬁcations of islet microenvironment in the liver
Recent characterization of islet engraftment at the
intraportal site has identiﬁed numerous problems
that need to be targeted to optimize graft survival
and function. However, since islets are dispersed and
embolized deep into the liver tissue at transplantation,
strategies to modify liver microenvironment per se are
difﬁcult. Instead such modiﬁcations must include the
systemic blood environment, or modiﬁcations of islet
tissue or surfaces prior to transplantation. In fact,
several strategies in order to intervene with IBMIR
have successfully been tested experimentally in vitro
and/or in vivo and include modiﬁcations of blood with
thrombin inhibition by megalatran (43), or with
low-molecular-weight dextran sulfate (44), or mod-
iﬁcations of the islets and their surfaces with nicotin-
amide (45), heparin (46), or endothelial coating (47).
At present, a clinical trial is conducted in the Nordic
countries investigating the effects of low-molecular-
weight dextran sulfate on outcome in patients trans-
planted intraportally with islets.
Different anti-apoptotic strategies have been tested
to improve early islet survival in experimental models.
Most successful studies include gene transfection
strategies difﬁcult to implement in the clinical situa-
tion. However, besides this, e.g. different caspase
inhibitor therapies of recipients (48), or even of islets
for transplantation (49), have proved effective in
improving outcome in minimal islet mass models in
mice. Moreover, merely prolactin or glucocorticoid
supplementation of the culture medium has been
shown to improve b-cell survival during human islet
culture and early after experimental islet transplanta-
tion (50–52). Also long-acting glucagon-like peptide 1
analogues improve human islet survival in culture
(53), protect murine b-cells of intraportal islet
transplants from apoptosis (54), and are beneﬁcial
for glucose homeostasis in marginal mass islet-
transplanted mice (55). One of these long-acting
glucagon-like peptide 1 analogues, exenatide, has
been introduced in clinical islet transplantation
protocols at some transplantation centres (56,57).
Our recent studies indicate that damage to islets at
intraportal transplantation may facilitate subsequent
islet revascularization, whereas islets with maintained
integrity are poorly revascularized and blood-perfused
(Henriksnäs J, Lau J, Zang G, Berggren P-O,
Köhler M, and Carlsson P-O; unpublished obser-
vation). Different means to improve islet revascular-
ization have been tested including over-expression
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growth factor (VEGF) in the islet tissue by virus
vectors (58). More recently, a non-viral gene
delivery approach has been successfully tested in a
small-animal model, where VEGF was delivered to
intraportally transplanted human islets by ultrasound-
targeted microbubble destruction (59). Translation
into the clinical situation may, however, be hampered
by technique limitations in penetration of ultrasound
in larger organs. More feasible in the clinical sett-
ing than trying to increase the expression of pro-
angiogenic factors in the islet tissue may be to inhibit
angiostatic factors. We recently showed proof of
principle by inhibition of the angiostatic factor
thrombospondin-1 in islets by a siRNA technique,
which improved both islet graft revascularization
and function (60). Unfortunately, at present there
are no pharmacological receptor antagonists for
thrombospondin-1 available. However, prolactin
was found to decrease the expression of
thrombospondin-1 in islets in culture and had bene-
ﬁcial effects for islet graft revascularization and func-
tion both when injected to recipient animals during
the ﬁrst days post-transplantation, or merely added
during culture of islets prior to transplantation (50).
Cell coating provides interesting aspects to bioen-
gineering of islets and to obtaining multiple effects
that can diminish adverse events following transplan-
tation. Besides previously mentioned endothelial
coating, other cell types might be considered for
modiﬁcation of islet surfaces. As reported in a paper
in the present issue of this journal, mesenchymal stem
cells (MSCs) form an interesting approach to provide
local immunosuppressive effects, at least early after
transplantation (61). Positive effects of MSCs on
revascularization in experimentally transplanted islets
have recently been shown in vivo (62), and these cells
can facilitate endothelial coating of the islet surface
in vitro as well (63). Several other cell types are of
interest to include in the islet microenvironment,
including endothelial progenitor cells and neural crest
stem cells. Endothelial progenitor cells seem to be
able to diminish innate immune reactions and
improve survival, revascularization, b-cell prolif-
eration, and function in islet grafts (64). Neural
crest stem cells have the ability to increase substan-
tially b-cell proliferation and improve islet graft
function (65).
Modiﬁcations of islet microenvironment in extrahepatic
sites
As described above, extrahepatic sites to some part
provide different challenges for survival and regain of
function when compared to the liver. There are also
site-speciﬁc differences to consider. In general, how-
ever, in most cases transplantation to these sites does
not include infusion of islets into blood, which
diminishes IBMIR. Some innate immune reactions
may remain, but the extent of these remains to be
elucidated. It can be envisaged that hypoxia in newly
transplanted avascular cells provides a limitation also
in extrahepatic sites, especially when islets are
implanted in clusters. Dispersion of islets at trans-
plantation is of great advantage, and techniques for
optimal implantation of islets need to be developed.
Modiﬁcations of islet microenvironment can at most
of these sites be obtained by the use of scaffolds and
biomaterial implanted before or together with the
islets in order to provide spatial and functional sup-
port for the islets (66). The biomaterials can be
biodegradable or not, and can also be modiﬁed e.g.
by inclusion of oxygen carriers such as polymerized
haemoglobin, anti-inﬂammatory components or
cells, and growth factors and cells to stimulate angio-
genesis. In this manner, also substances and cells
that do not readily adhere to islet surfaces can be
used to modify islet microenvironment and create
new micro-organs. Studies are on-going to optimize
such micromilieus.
Conclusions
In recent years, several hurdles that restrict the suc-
cess of pancreatic islet transplantation into the liver
have been identiﬁed. Possible solutions to some of
these problems have also been tested and include
interventions to the IBMIR and means to improve
revascularization. In parallel, there has been an
increased interest in change of implantation site in
order to avoid the site-speciﬁc problems of the intra-
portal route. Most alternative implantation sites have,
however, not been well characterized with regard to
engraftment of islets, and many unidentiﬁed obstacles
at alternative locations may remain. New strategies
with modiﬁcations of the islet microenvironment with
cells and growth factors adhered to the islet surface or
in a surrounding matrix provide possibilities to
improve results of islet transplantation irrespective
of implantation site. Such technologies may also
pave the way for future improvements of the matu-
ration and function of stem cells as a surrogate for
native b-cells in vivo.
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